An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

NCT01772823 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection

Interventions

BEHAVIORAL: 3MV
BEHAVIORAL: PCC
DRUG: Emtricitabine/tenofovir (FTC/TDF (Truvada®))

Sponsor

University of North Carolina, Chapel Hill

Collaborators

[object Object]
[object Object]